baber/WOPTO huggingface dataset:
Patent JP-2001501568-A (JP)
IPC: B66F3/35
Filed: 1997-03-26
Abstract: PCT No. PCT/SE97/00545 Sec. 371 Date Nov. 9, 1998 Sec. 102(e) Date Nov. 9, 1998 PCT Filed Mar. 26, 1997 PCT Pub. No. WO97/36818 PCT Pub. Date Oct. 9, 1997The invention relates to a vacuum hoisting device of the kind having a vertically suspended lifting tube (4), which is extensible and contractible depending upon the air pressure in the lifting tube, and which at its lowest part is provided with a suction device (6) in the shape of one or more suction cups. Up to now, a valve at the suction device has been used for maneuvering the suction device, which valve when closed brings a vacuum source (7,20) to work with a constant suction capacity to decrease the pressure in the lifting tube such that an object (32) to be lifted is attached by the suction after which the lifting tube is contracted such that the object is lifted. To limit the lifting height and to lower and release the object, it has been necessary to partially open the valve and permit a restricted inlet of air and at last completely open the valve resulting in a large consumption of air. According to the invention, there is instead a valve (14,23) arranged to control the suction capacity of the vacuum source in direct dependence on the desired air pressure in the lifting tube (4).
Patent JP-H10510336-A (JP)
IPC: E02D17/20
Filed: 1996-05-31
Abstract: The invention relates to a textile composite material used to stabilize, consolidate or reinforce soils and layers of earth, and which can also be used as a load-carrying drainage or filtering layer and comprises at least one nonwoven fabric (1). The disadvantage of nonwovens, used alone or in textile composites made of various plastic nonwovens, lies in their limited load-carrying capacity. To create a low cost textile composite material comprising at least one nonwoven fabric, having a high tear resistance in a main load direction and the ability to absorb high tensile forces without undue stretching, exclusively parallel, straight, load-carrying plastic filament yarns (2) are knitted, sewed or Raschel-knitted onto the nonwoven (1).
Patent JP-2001527608-A (JP)
IPC: A47G27/02
Filed: 1998-02-27
Abstract: The present invention pertains to carpet and methods of making carpet. In one aspect, the carpet includes (a) a primary backing which has a face and a back surface, (b) a plurality of fibers attached to the primary backing and extending from the face of the primary backing and exposed at the back surface of the primary backing, (c) an adhesive backing, (d) an optional secondary backing adjacent to the adhesive backing, and (e) at least one homogeneously branched ethylene polymer. The method includes extrusion coating at least one homogeneously branched ethylene polymer onto the back surface of a primary backing to provide an adhesive backing. The method can include additional steps or procedures, either separately or in various combinations. Additional steps and procedures include washing or scouring the primary backing and fibers prior to the extrusion step, and utilizing implosion agents. The preferred homogeneously branched ethylene polymer is a substantially linear ethylene polymer. The constructions and methods described herein are particularly suited for making tufted, broad-loom carpet having improved abrasion resistance.
Patent JP-2001519944-A (JP)
Title: コンピュータ制御の顕微鏡から試料の拡大イメージを取得し再構成するための方法および装置
IPC: G02B21/00
Filed: 1998-03-02
Abstract: (57)【要約】
コンピュータ制御された顕微鏡（１６）が複数のイメージを低倍率で捕捉する。これらのイメージはタイル状に並べられ、試料全体の再構成されたイメージ（２４）を作成する。ユーザは再構成されたイメージの１つあるいは複数の領域を選択する。コンピュータ制御された顕微鏡（１６）はそれから、選択された領域について複数の高解像度のイメージ（２６）を捕捉し、ユーザに表示する。
Patent JP-2001522454-A (JP)
Title: 細胞応答への影響に関する定量情報の抽出方法
IPC: G01N33/50
Filed: 1998-04-07
Abstract: (57)【要約】
細胞は、遺伝的に修飾されて、発光団、例えば転写因子、cGMP-又はcAMP-依存性プロテインキナーゼ、サイクリン-、カルモジユリン-又はリン脂質-依存性、又はマイトジェン活性化セリン/スレオニンプロテインキナーゼ、チロシンプロテインキナーゼ又はプロテインホスファターゼ(例えば、PKA、PKC、Erk、Smad、VASP、アクチン、p38、Jnk1、PKG、IkappaB、CDK2、Grk5、Zap70、p85、プロテインチロシンホスファターゼ1C、Stat5、NFAT、NFkappaB、RhoA、PKB)のような細胞内シグナル経路の成分に結合した修飾(F64L、S65T、Y66H)緑色蛍光タンパク質(GFP、EGFP)を発現する。この作用により、影響の程度に関連することが実験的に決定される方法で、発光団が再分布されるか、又は生細胞の成分で転位されるように、細胞内シグナル経路がモジュレートされる。再分布測定は、例えば蛍光顕微鏡及びCCDカメラからなる装置で光強度、蛍光寿命、偏向、波長シフト、共鳴エネルギー転移又は他の性質を記録して行われる。デジタル画像として蓄積したデータは、再分布の程度を示す数に処理される。この方法は、成分をモジュレートし、成分の機能に関連した疾患の治療ができる化合物を同定するスクリーニングプログラムとして用いることができる。
Patent JP-2000500916-A (JP)
IPC: H01J61/067
Filed: 1998-03-20
Abstract: A gas discharge lamp having a discharge vessel (202) which is at least partially transparent and filled with a gas filling, a number of essentially strip-shaped anodes (205, 206) and cathodes (203, 204) which extend on the walls of the discharge vessel and essentially parallel to each other, and a dielectric layer (215) between at least the anodes and the gas filling for a dielectrically impeded discharge in the discharge vessel between neighboring anodes and cathodes, characterized in that at least one anode pair (205) is arranged between two cathodes (203, 204) respectively adjacent to one anode pair.
Patent JP-2000515563-A (JP)
Title: ポリα−オレフィン油を含むヘアーコンディショニング組成物
IPC: A61K8/89
Filed: 1998-06-04
Abstract: (57)【要約】
（１）炭素原子約６ないし約１６個の１−アルケンモノマー類から誘導されるポリα−オレフィン油であって、約１ないし約３５,０００ｃｓｔの粘度、約２００ないし約６０,０００の分子量、および最高約３の多分散性を有するポリα−オレフィン油と；（２）親水性置換カチオン性界面活性剤、アミン類、高融点化合物およびこれらの混合物からなる群から選択される付加的コンディショニング剤と；（３）水性担体とを含んでなるコンディショニングシャンプー組成物が開示されている。
Patent MD-20030163-A (MD)
Inventor: POPEL SVETLANA
IPC: A23L33/00
Filed: 2003-07-02
Abstract: Inventia se refera la industria alimentara, in special la o compozitie si un procedeu de fabricare a compoturilor conservate cu proprietati functionale de caracter diabetic. Compotul contine urmatoarele componente, in % de masa: visine cu samburi sau fara samburi 45...51; zmeura 14...19; siropul din extract apos de stevie (cu continutul masic de glicozide 0,15...0,22%) 35...36. Procedeul de obtinere a compotului include pregatirea visinelor si a zmeurii, prepararea siropului, ambalarea visinelor si a zmeurii in recipiente, turnarea siropului, inchiderea si sterilizarea. Siropul pentru turnarea in recipiente se pregateste din extract apos de stevie cu continutul masic de glicozide 0,15...0,22%. Inainte de turnare in recipiente siropul se fierbe timp de 3...5 min. Rezultatul inventiei este obtinerea produsului cu proprietati functionale de caracter diabetic, imbogatit cu aminoacizi, vitamine, polifenoli si elemente minerale. ŕ
Patent MX-155973-A (MX)
Inventor: FREEMAN JOSEPH WAYNE
IPC: G06F1/00
Filed: 1984-08-09
Abstract: Cartridges for a microcomputer have two adjacent edge connectors replaced by a single connector (14) with a projection (29) which passes into the area in which the adjacent connector would normaliy be placed. When the cartridge is inserted or removed from the connector socket (3) in the microcomputer, the projection transiently shorts a pair associated socket contacts (27,28). A fixed potential (for example earth potential) normally applied to the main portion of the edge connector from its associated contact (28) of the pair is therefore transferred to the transiently contacted contact (27) to provide a reset signal for the microprocessor of the microcomputer. Thus, the microprocessor is reset each time a cartridge is inserted or withdrawn.
Patent NZ-229345-A (NZ)
Title: Substituted butenoic or propenoic acid (thio)amides and pharmaceutical compositions
Inventor: NORIO MINAMI
IPC: C07D213/64
Filed: 1989-05-30
Abstract: A butenoic or propenoic acid derivative having the following formula in which G is an aryl or a heterocyclic ring, R11 and R12 are hydroben or an alkyl, X is sulfur or oxygen, R2 and R3 are hydrogen, an substituent such as an alkyl and J is pyridyl or phenyl having substituents and a heterocyclic ring may be formed between R2, R3 and J is provided here and is useful in the pharmacological field. <CHEM> t
Patent NZ-231091-A (NZ)
Title: Contraception system and method comprising timed administration of an estrogen followed by a progestin
Inventor: PASQUALE SAMUEL ANTHONY
IPC: A61K31/565
Filed: 1989-10-20
Abstract: A method of contraception is disclosed which comprises a two-stage protocol. In the first stage, an estrogenic compound in a first composition is administered daily as the sole contraceptively active substance to a human female from about Day 2 to about Day 7 of her menstrual cycle, where Day 1 is the first day of menses. The second stage of the protocol occurs immediately thereafter during which at least one follow-up composition containing a progestin is administered daily to the same human female. The follow-up composition can contain a progestin as the sole contraceptively active ingredient, or can contain a combination of an estrogenic compound with a progestin in different weight ratios. A drug delivery system containing daily dosage units is also described.
Patent NZ-231576-A (NZ)
Title: Nucleic acid sequencing following amplification involving amplification primer containing nucleotide bound to an attachment moiety
Inventor: SODERLUND HANS ERIK
IPC: C12Q1/68
Filed: 1989-11-29
Abstract: The invention provides for detection of changes in a nucleotide sequence based on the determination of the nucleotide sequence over the region of interest. The first step of the process involves obtaining an amplified DNA sample in which at least one attachment moiety has been introduced into at least one strand of a target polynucleotide by a modified polymerase chain reaction. This can be accomplished by synthesizing DNA using the target nucleic acid polymer as a template and using at least one amplification primer, which includes an attachment moiety bonded to the oligonucleotide. The resulting amplification mixture is repeatedly cycled between a polymerization condition and a denaturation condition occurs for a number of cycles sufficient to produce copies of the target nucleic acid polymer in a quantity suitable for use in a DNA sequencing procedure to form an amplified sample comprising copies of the target nucleic acid sequence bonded to the attachment moiety. After amplification, the strands of target nucleic acid polymer carrying an attachment moiety are captured using a solid matrix coated with an attachment site to which the attachment moiety or a modification thereof can bind. In this way, the strands of target nucleic acid become bound to the solid matrix and can be readily separated with the solid matrix from unbound reactants for sequencing.
Patent NZ-235316-A (NZ)
Title: Vaccine containing capsular polysaccharide conjugated to recombinant c protein of a group b streptococcus, production and use against b streptococcus infection
Inventor: MICHEL JAMES L
IPC: A61P31/12
Filed: 1990-09-14
Abstract: A vaccine capable of protecting a recipient from infection caused by group B Streptococcus. The vaccine is formed by conjugating (a) a polysaccharide conjugated to (b) a protein; wherein both the polysaccharide and the protein are characteristic molecules of the group B Streptococcus.
Patent NZ-250800-A (NZ)
Title: Indole, indazole and benzisoxazole derivatives and pharmaceutical compositions thereof
Inventor: LAVIELLE GILBERT
IPC: A61K31/40
Filed: 1994-02-01
Abstract: The invention relates to the compounds of formula (I): <IMAGE>  in which:   R1 represents a hydrogen or halogen atom, an alkyl, alkoxy, cyano or aminocarbonyl group or any one of the following groups: <IMAGE>  -(CH2)m-NH-COR6, -(CH2)m-NH-SO2-R4, <IMAGE>  -(CH2)m-NH-CO-NHR4, <IMAGE>  -(CH2)m-SO2-NH-R4, -CH=CH-SO2-NH-R4, <IMAGE>  in which:     m is equal to 1, 2 or 3,   n is equal to 0, 1 or 2,   T represents a CO or SO2, R4 or R5, which are identical or different, represent a hydrogen atom or an alkyl or phenyl group,     R2 represents a hydrogen atom or an alkyl, phenyl or acyl group, R3 represents a hydrogen atom or an alkyl (optionally substituted by a hydroxyl or phenyl group) or alkoxycarbonyl group,   -X-Y= represents -N-C=, -N-N= or else <IMAGE>  represents -O-N=, to their enantiomers, diastereoisomers and epimers and to their addition salts with a pharmaceutically acceptable acid. Medicaments.
Patent NZ-309991-A (NZ)
Title: Using pentonsan polysulphate to treat chronic progressive vascular diseases
Inventor: STRIKER GARY E
IPC: A61K31/737
Filed: 1996-06-03
Abstract: Provided is the treatment of chronic progressive vascular disease, characterized by scarring and/or fibrosis in an affected organ or vasculature, to halt the progress of the disease and cause the resolution of already formed scarring or fibrotic lesions, using pentosan polysulfate.
Patent NZ-332597-A (NZ)
Title: Alkyloxyamino substituted fluoren-9-ones and their use as protein kinase c inhibitors
Inventor: JONES WINTON D
IPC: A61P29/00
Filed: 1997-04-24
Abstract: The fluoren-9-one compound or a salt thereof has the formula I wherein: B is O, S or NH; each R4 is independently methyl, ethyl or n-propyl or both R4 groups can together form a pyrrolidinyl, piperidinyl or morphlino; R5 is alkylene; V is H, methoxy, ethoxy, n-propoxy or butoxy; X is H, methoxy, ethoxy, n-propoxy, F or Cl; Y is H, NH2, NHR, NHCOR with R being alkyl or phenyl and Z is H, alkyl, F, Cl, BR5N(R4)2 wherein B, R4 and R5 are as defined above; limited by the proviso as defined in the specification. The fluoren-9-one compounds are useful for inhibiting protein kinase C, treating neoplastic disease states, inhibiting angiogenesis, treating abnormal blood flows, inhibiting platelet aggregation or inhibiting inflammation in a patient.
Patent NZ-333535-A (NZ)
Title: Coin discrimination apparatus and method
Inventor: MARTIN DOUG
IPC: G07D5/08
Filed: 1997-06-27
Abstract: A coin discrimination apparatus and method is provided. Coins, preferably after cleaning, e.g. using a trommel (not shown), are singulated by a coin pickup assembly configured to reduce jamming. A coin rail (56) assists in providing separation between coins as they travel past a sensor (58). The sensor provides an oscillating electromagnetic field generated on a single sensing core (214). The oscillating electromagnetic field is composed of one or more frequency components. The electromagnetic field interacts with a coin, and these interactions are monitored and used to classify the coin according to its physical properties. Objects recognized as acceptable coins, using the sensor data, are diverted by a controllable deflecting door (62), to tubes for delivery to acceptable coin bins (not shown).
Patent NZ-335592-A (NZ)
Title: Composition containing an exogenous chemical and a quaternary ammonium excipient for treating plant
Inventor: WARD ANTHONY J I
IPC: A01N25/04
Filed: 1997-10-24
Abstract: The plant treatment composition comprises: (a)	an exogenous chemical, and (b)	a first excipient substance that is an amphiphilic quaternary ammonium compound or mixture of such compounds having the formula R8-Wa-X-Yb-(CH2)n-N+(R9)(R10)(R11)T wherein R8 is a hydrocarbyl or haloalkyl group; W and Y are independently 0 or NH; a and b are independently 0 or 1 but at least one of a and b is 1; X is CO, SO or SO2; n is 2 to 4; R9, R10 and R11 are independently alkyl and T is a suitable anion.  The weight ratio of the first excipient substance to the exogenous chemical is between about 1:3 and about 1:100.  The exogenous chemical can be a herbicide, nematicide or plant growth regulator such as  an acetanilide, cyclohexenone, fatty acid, hydroxybenzonitrile, imidazolinone, phenoxypropionate, substituted urea, sulphonylurea, thiocarbamate or triazine.
Patent NZ-503538-A (NZ)
Title: Moxifloxacin formulation characterised by the release times containing hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder and ethylcellulose as film forming polymer
Inventor: STASS HEINO
IPC: A61P31/04
Filed: 1998-09-15
Abstract: A medicament formulation comprising 1-cyclopropyl-7-([S,S]-2,8-diazabicyclo[4.3.0]non-8-yl)-6- fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolone carboxylic acid and/or pharmaceutically compatible salts thereof as an active agent. The medicament formulation is characterised in that the average release rate of the formulation is between 80% in 2 hours and 80% in 16 hours and an initial release of less than 60% of the active agent in the first hour of release. The formulation is further characterised in that it contains hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder, ethylcellulose as film forming polymer and a plasticiser.
Patent NZ-505675-A (NZ)
Title: N-alkylamide substituted hydroxamic acid derivatives are used as antibacterial agents
Inventor: HUNTER MICHAEL GEORGE
IPC: A61K31/445
Filed: 1999-02-05
Abstract: An N-formyl hydroxylamine derivative of formula (I) H-C(=O)-N(OH)-C(H)(R1)-C(H)(R2)-C(=O)-A or a pharmaceutically or veterinarily acceptable salt thereof is used to treat bacterial infections. In formula (I) R1 is hydrogen, alkyl or halo alkyl;  R2 is R10-(X)n-(ALK)m-; R10 is hydrogen or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, or heterocyclic group; ALK is divalent alkylene alkenylene, or alkynylene radical, and may be interrupted by one or more non-adjacent -NH-, -O- or -S- linkages; X is -NH-, -O- or -S-; m and n are independently 0 or 1; A is -N(R3)-C(H)(R4)-C(=O)-N(R6)-R5, -N(R3)-C(H)(R4)-C(=O)-OH, -N(R3)-C(H)(R4)-CH2-O-R7 or -N(R6)-R5; R3 is hydrogen and R4 is the side chain of a natural or non-natural -a-amino acid or R3 and R4 when taken together with the nitrogen and carbon atoms to which they are respectively attached form an optionally substituted saturated heterocyclic ring of 5 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring; R5 and R6, independently represent hydrogen or optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heterocyclic, or heterocycloalkyl, or R5 and R6 when taken together with the nitrogen atom to which they are attached form an optionally substituted saturated heterocyclic ring of 3 to 8 atoms which ring is optionally fused to a carbocyclic or second heterocyclic ring and R7 is hydrogen, alkyl, or an acyl group.
Patent NZ-506466-A (NZ)
Title: Method of producing mouse and human endostatin
Inventor: HARDING ELIZABETH I
IPC: A61K38/12
Filed: 1999-02-19
Abstract: A method of producing soluble refolded endostatin comprises the steps of: (a) culturing host cells that are expressing an endostatin gene; (b) recovering the product of the gene expression; (c) solubilizing said gene product at about pH 9 to 11.5; (d) refolding the gene product at about pH 6 to 8.5 in the presence of a concentration of denaturant selected from about 2M to about 4M urea and about 0.2M to 2M guanidine hydrochloride and; and (e) isolating properly folded forms of the gene product. Or the steps of: (a) culturing host cells that are expressing an endostatin gene; (b) recovering the product of the gene expression; (c) refolding the gene product at about pH 6 to 8.5 in the presence of a concentration of denaturant selected from about 2M to about 4M urea and about 0.2M to 2M guanidine hydrochloride and; and (d) isolating properly folded forms of the gene product. Also described is a method for producing soluble refolded endostatin from inclusion bodies prepared from bacteria .
Patent NZ-511561-A (NZ)
Title: Sliding doors and windows with fixed and moving seal elements that cooperate with each other
Inventor: BEVAN GLENN MICHAEL
IPC: E06B7/26
Filed: 1999-10-29
Abstract: Disclosed are sealing arrangements for windows and doors, and in particular to sealing arrangements for sliding windows and doors. Relating  to a sealing arrangement for a sliding window or door, the sliding window or door including a fixed sash (4) and a sliding sash (2) movable between a closed position and an open position, the fixed and sliding sashes including respective frame members (5, 6) which are positioned adjacent each other when said sliding sash is moved to said closed position, the sealing arrangement including a fixed seal element and a moving seal element, the moving seal element carried on said sliding sash (2), wherein upon moving the sliding sash to the closed position the fixed and moving seal elements cooperate with each other to provide a seal at an end of said adjacent frame members (5, 6).
Patent NZ-514153-A (NZ)
Title: Optically pure camptothecin analogues
Inventor: LAVERGNE OLIVIER
IPC: A61P33/00
Filed: 2000-02-24
Abstract: Use of compounds of formula (I) wherein R1 represents a lower alkyl radical; R2, R3, R4, and R5 independently represent H or OSO2R10; R6, R7, R8, R9 and R10 represent different variable groups.  Said compounds have anti-proliferative activity in cancerous cell lines.
Patent NZ-516746-A (NZ)
Title: Lactams substituted by cyclic succinates as inhibitors of A-beta protein production
Inventor: OLSON RICHARD E
IPC: A61K31/553
Filed: 2001-06-01
Abstract: This invention relates to novel lactams having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aâ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to â-amyloid production such as Alzheimer's disease and Down's Syndrome.
Patent NZ-516756-A (NZ)
Title: Detection of micro-organisms
Inventor: KEENAN ELIZABETH ANN
IPC: C12N1/02
Filed: 2000-08-07
Abstract: A method for recovering microorganisms from a sample mixture, comprising the steps of: 1) passing the sample mixture through the sample inlet of a filter device comprising a plurality of hollow fibre filter membranes which have been pretreated with a detergent, said membranes having first and second ends, and an outer surface and an inner surface defining a lumen, the first end of each of said membranes being open and communicating with said sample inlet and flow from the second being restricted such that said sample mixture is filtered through said membranes, leaving a filtrand in said lumen of said membranes: 2) re-suspending said filtrand in said membranes; and 3) detecting the presence of any microorganisms in said filtrand.
Patent NZ-526314-A (NZ)
Title: Methods and devices for radiofrequency electrosurgery
Inventor: LEE ROBERTA
IPC: A61B18/12
Filed: 2001-12-03
Abstract: An electrosurgical device (200) is disclosed. The electrosurgical device (200) includes: (a) a body (202) whereby the body (202) defines an outer surface, a proximal end (230), a distal end (208) and a window (204) defined within the outer surface, (b) an electrically insulating layer, retractably disposed across the window, and (c) an active element (206) whereby the active element (206) is adapted to connect to an electric power source (240). The electrosurgical device is configured so that it may selectively assume a non-deployed configuration in which the insulating layer electrically insulates the active element (206), and a variable deployed configuration, in which the electrically insulating layer is at least partially retracted from across the window (204) whereby the active element (206) at least partially emerges from the window (204) and out of the body (202).